Last $1.80 USD
Change Today 0.00 / 0.00%
Volume 0.0
WGBS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 04/14/14 All times are local (Market data is delayed by at least 15 minutes).

wafergen bio-systems inc (WGBS) Snapshot

Open
$1.45
Previous Close
$1.80
Day High
$1.80
Day Low
$1.45
52 Week High
05/21/13 - $5.96
52 Week Low
12/17/13 - $1.20
Market Cap
16.4M
Average Volume 10 Days
1.1K
EPS TTM
$-18.86
Shares Outstanding
9.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WAFERGEN BIO-SYSTEMS INC (WGBS)

Related News

No related news articles were found.

wafergen bio-systems inc (WGBS) Related Businessweek News

No Related Businessweek News Found

wafergen bio-systems inc (WGBS) Details

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. The company offers SmartChip Real-Time PCR system, which provides a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of real-time polymerase chain reaction (PCR). Its SmartChip Real-Time PCR system consists of two instrumentation components comprising a SmartChip MultiSample Nanodispenser for applying sample, assay, and reaction mix to the SmartChip Panels; and a SmartChip Cycler for thermal cycling and collecting data from the real-time PCR assays. The company also provides SmartChip Target Enrichment system for performing a sample preparation step prior to targeted next-generation sequencing (NGS); and Apollo 324TM System, a walk-away automation platform that offers DNA, RNA-Seq, and ChIP-Seq library preparation kits for analysis on NGS platforms. The company focuses on providing its products to researchers who perform genetic analysis, primarily at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker discovery and genetic research. WaferGen Bio-systems, Inc. was founded in 2002 and is headquartered in Fremont, California.

28 Employees
Last Reported Date: 03/14/14
Founded in 2002

wafergen bio-systems inc (WGBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $720.0K
Compensation as of Fiscal Year 2013.

wafergen bio-systems inc (WGBS) Key Developments

WaferGen Biosystems, Inc. Announces Executive Changes

WaferGen Biosystems, Inc. announced that on March 21, 2014, the company board of directors retained Stephen T. Baker to serve as Chief Financial Officer. Mr. Baker will serve as Chief Financial Officer and principal financial and accounting officer and will replace John Harland who submitted his resignation on March 18, 2014, effective as of April 15, 2014. Mr. Baker has served as a Chief Financial Officer at Frontrange Solutions, Roamware, and Geoworks Corporation.

WaferGen Biosystems, Inc., Q4 2013 Earnings Call, Mar 24, 2014

WaferGen Biosystems, Inc., Q4 2013 Earnings Call, Mar 24, 2014

WaferGen Biosystems, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

WaferGen Biosystems, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. Total revenue was $490,000, up 55% from $316,177 in the fourth quarter of 2012. Net income was $1.5 million compared to a net loss of $1.0 million in the fourth quarter of 2012. The net income was primarily due to one-time gains of $1.0 million on the settlement of the Series B convertible preferred shares of Malaysian subsidiary and $3.4 million when its liquidation commenced. Operating loss was $2,134,113 compared to $1,991,618 a year ago. Net income before provision for income taxes was $1,489,875 compared to net loss before provision for income tax of $1,068,955 a year ago. Net income attributable to common stockholders was $4,385,275 or 0.25 per diluted share compared to net loss of $1,238,890 or $2.95 per diluted share a year ago. For the year, the company’s total revenue more than doubled to $1,304,747 compared to $586,176 in 2012. The year's net loss was $16.3 million compared to a net loss of $8.2 million in 2012. The increase in the net loss was attributable to non-cash, non-operating expenses largely relating to the capital restructuring that occurred in the third quarter. Operating loss was $9,922,443 compared to $9,765,976 a year ago. Net loss before provision for income taxes was $16,259,931 compared to $8,198,115 a year ago. Net loss attributable to common stockholders was $17,712,066 or 5.82 per diluted share compared to $8,978,196 or $21.42 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WGBS:US $1.80 USD 0.00

WGBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $6.91 USD +0.10
Fluidigm Corp $35.97 USD +1.16
Luminex Corp $17.07 USD +0.32
NanoString Technologies Inc $15.62 USD +0.01
Sequenom Inc $2.57 USD +0.065
View Industry Companies
 

Industry Analysis

WGBS

Industry Average

Valuation WGBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WAFERGEN BIO-SYSTEMS INC, please visit www.wafergen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.